» Articles » PMID: 15541644

Zinc Transporter LIV-1: a Link Between Cellular Development and Cancer Progression

Overview
Specialty Endocrinology
Date 2004 Nov 16
PMID 15541644
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Genes involved in normal developmental processes often have a role in tumour progression. Epithelial-mesenchymal transition (EMT) is a general phenomenon that is an essential event in embryonic development, tissue remodelling and wound repair. Genes that regulate EMT are attracting significant attention as mediators of tumour progression. Indeed, EMT is considered an important event during the evolution of malignant tumours and their progression to metastasis, with several reports of molecules involved in this process facilitating migration and invasion of epithelial tumour cells. Recent work linking the zinc transporter LIV-1 with the transcription factors STAT3 and Snail in zebrafish embryogenesis, throws new light on this transition and has important implications for the development of cancer.

Citing Articles

Antibody-Drug Conjugates: A New Therapeutic Approach for Triple-Negative Breast Cancer.

Al Jarroudi O, El Bairi K, Curigliano G, Afqir S Cancer Treat Res. 2024; 188:1-27.

PMID: 38175340 DOI: 10.1007/978-3-031-33602-7_1.


Exploring the therapeutic potential of ADC combination for triple-negative breast cancer.

Lu L, Niu Z, Chao Z, Fu C, Chen K, Shi Y Cell Mol Life Sci. 2023; 80(12):350.

PMID: 37930428 PMC: 11073441. DOI: 10.1007/s00018-023-04946-x.


Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.

Nader-Marta G, Molinelli C, Debien V, Martins-Branco D, Aftimos P, de Azambuja E Ther Adv Med Oncol. 2023; 15:17588359231183679.

PMID: 37435563 PMC: 10331351. DOI: 10.1177/17588359231183679.


Editorial: Advances in genomic and genetic tools, and their applications for understanding embryonic development and human diseases.

Abu-Elmagd M, Assidi M, Alrefaei A, Rebai A Front Cell Dev Biol. 2022; 10:1016400.

PMID: 36478744 PMC: 9720382. DOI: 10.3389/fcell.2022.1016400.


The importance of targeting signalling mechanisms of the SLC39A family of zinc transporters to inhibit endocrine resistant breast cancer.

Jones S, Farr G, Nimmanon T, Ziliotto S, Gee J, Taylor K Explor Target Antitumor Ther. 2022; 3(2):224-239.

PMID: 35591900 PMC: 7612740. DOI: 10.37349/etat.2022.00080.